Great news for BioSpecifics investors. A FDA panel today backed Xiaflex as a treatment for Dupuytren's disease. The vote was unanimous.
Great news for BioSpecifics investors. A FDA panel today backed Xiaflex as a treatment for Dupuytren's disease. The vote was unanimous.